The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to The Harvard Drug Group, L.L.C. DBA Major Pharmaceuticals and Rugby Laboratories to supply tamsulosin hydrochloride capsules. The single award contract has a potential value of $62.9 million and a period of performance of June 1, 2022 through May 31, 2023 with four one-year option periods. Delivery will be made to the VA, DoD, Bureau of Prisons, and Indian Health Service through the pharmaceutical prime vendor programs.
The originating pre-solicitation notice sought offers for an unrestricted procurement of tamsulosin capsules in 90 count, 500 count, and 1000 count bottle sizes. Annual estimated requirements total over 2 million bottles across the three sizes to supply the medication to VA, DoD, BOP and IHS customers. The solicitation was issued pursuant to FAR Part 12 for commercial items with North American Industry Classification System code 325412 and no set aside designation. The awarded contractor will provide an uninterrupted supply of the generic prostate medication to meet patient needs across the agencies.
Generated 1/4/24, 11:31 PM